Physician profile
Qasim Butt
NPI 1598966715
$13,236.91
in general payments reported to CMS, 2019-2025
26 companies · $3,638 in 2025
The $3,638 reported for 2025 was more than what 92% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,022 · 2020: $633 · 2021: $2,040 · 2022: $808 · 2024: $5,096 · 2025: $3,638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,096 · Honoraria: $3,500 · Food and Beverage: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,096.00 |
| Honoraria | $3,500.00 |
| Food and Beverage | $137.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $5,307.53 | 2019-2024 | |
| Scpharmaceuticals INC. | $3,623.92 | 2025 | |
| Osprey Medical INC | $1,500.00 | 2021 | |
| Access Vascular INC | $650.00 | 2022 | |
| Bard Peripheral Vascular, INC. | $511.83 | 2019-2021 | |
| Fresenius USA Marketing, INC. | $221.40 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $199.01 | 2019 | |
| Opko Pharmaceuticals, LLC | $161.14 | 2019-2021 | |
| Baxter Healthcare | $159.12 | 2019-2022 | |
| Horizon Therapeutics Plc | $131.61 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $124.99 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $80.76 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $71.65 | 2019-2025 | Jynarque |
| Novartis Pharmaceuticals Corporation | $71.36 | 2019-2021 | |
| Nxstage Medical, INC. | $69.45 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $67.49 | 2022 | |
| Mallinckrodt Hospital Products INC. | $64.54 | 2020 | |
| Amgen INC. | $47.57 | 2019 | |
| Janssen Pharmaceuticals, INC | $35.15 | 2021 | |
| Cardiovascular Systems INC. | $32.58 | 2019 | |
| Argon Medical Devices, INC. | $24.04 | 2021 | |
| Biocompatibles, INC. | $20.95 | 2019 | |
| Cook Medical LLC | $20.81 | 2021 | |
| Covidien Lp | $19.15 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.48 | 2019 | |
| Outset Medical INC | $6.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Qasim Butt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.